Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Jasper Therapeutics Inc (NASDAQ: JSPR) is a clinical-stage biotechnology company pioneering safer conditioning agents for stem cell transplants and gene therapies. This dedicated news hub provides investors and medical professionals with timely updates on clinical developments, regulatory milestones, and strategic partnerships central to advancing curative treatments.
Discover comprehensive coverage of JSPR's progress in hematopoietic stem cell research, including trial results for jsp191 and related therapeutic platforms. Our curated collection features press releases on FDA interactions, collaboration announcements with research institutions, and analyses of scientific breakthroughs in antibody-based conditioning.
Key updates include progress reports on:
• Phase clinical trials evaluating novel conditioning regimens
• Strategic licensing agreements enhancing therapeutic pipelines
• Peer-reviewed research publications validating scientific approaches
• Financial disclosures supporting continued R&D efforts
Bookmark this page for direct access to Jasper Therapeutics' official communications and third-party analyses, carefully vetted for accuracy and relevance. Check regularly for developments that could influence the future of stem cell transplantation protocols and gene therapy accessibility.
Jasper Therapeutics (JSPR) reported its Q4 and full-year 2024 financial results, highlighting significant progress in clinical trials for briquilimab, their novel antibody therapy. The company reported positive data from two key studies: the BEACON study in chronic spontaneous urticaria (CSU) and the SPOTLIGHT study in chronic inducible urticaria (CIndU).
Key clinical achievements include rapid and deep response profiles in urticaria patients, with weekly score improvements exceeding 25 points in doses ≥120mg. In the SPOTLIGHT study, 93% of participants achieved clinical response, with 83% experiencing complete response in the 120mg dose cohort.
Financial results show $71.6 million in cash and equivalents as of December 31, 2024. The company reported Q4 R&D expenses of $19.8 million, G&A expenses of $5.5 million, and a net loss of $24.3 million ($1.62 per share). Full-year 2024 resulted in a net loss of $71.3 million ($4.89 per share).
Jasper Therapeutics (Nasdaq: JSPR), a clinical stage biotech company developing briquilimab, announced its participation in three major investor conferences this March. The company, which focuses on developing novel antibody therapy targeting c-Kit (CD117) for mast cell driven diseases including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, will present at:
- TD Cowen 45th Annual Healthcare Conference (March 3-5, 2025) with presentation on March 3 at 1:20 p.m. EST
- Barclays 27th Annual Global Healthcare Conference (March 11-13, 2025)
- H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025 at 12:30 p.m. EST
Live webcasts will be available on Jasper's Investor Relations website with 30-day replay access.
Jasper Therapeutics (Nasdaq: JSPR) has announced multiple presentations of data for its novel antibody therapy briquilimab at the upcoming AAAAI 2025 Annual Meeting in San Diego. The presentations include five posters and one oral session, scheduled for February 28 - March 3, 2025.
The presentations will feature additional follow-up data from the Phase 1b/2a BEACON trial evaluating briquilimab in chronic spontaneous urticaria (CSU), expanding on preliminary data disclosed on January 8th, 2025. The research focuses on briquilimab's targeting of c-Kit (CD117) for treating mast cell driven diseases including CSU, chronic inducible urticaria (CIndU), and asthma.
The presentations will cover various aspects of briquilimab's mechanism of action, including its ability to deplete mast cells across multiple tissues, inhibit stem cell factor signaling, and its effectiveness in dermatitis mouse models.
Jasper Therapeutics (Nasdaq: JSPR) has announced its participation in the upcoming Oppenheimer Healthcare Life Sciences Conference, scheduled for February 11-12, 2025. The company will present in a fireside chat format on Tuesday, February 11, 2025, at 3:20 p.m. EST.
Jasper is a clinical stage biotechnology company developing briquilimab, a novel antibody therapy targeting c-Kit (CD117). The therapy aims to address mast cell driven diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma.
The presentation will be available via live webcast on Jasper's Investor Relations website under the News & Events – Events page. An archived version will remain accessible for 30 days following the live broadcast.
Jasper Therapeutics (JSPR) reported positive preliminary data from its BEACON Phase 1b/2a study of briquilimab in treating Chronic Spontaneous Urticaria (CSU). The study showed significant clinical responses across multiple dosing cohorts, with the 240mg single-dose group achieving a mean UAS7 change of -26.6 from baseline at 8 weeks.
Key highlights include 100% Complete Response (UAS7 = 0) in the 240mg single-dose cohort (N=3) at 8 weeks, with 66% maintaining Well Controlled disease at 12 weeks. Multiple dosing regimens ≥120mg demonstrated UAS7 changes exceeding -25 points. The drug showed rapid onset of action, with responses observed as early as 1-week post-first dose.
Briquilimab demonstrated a favorable safety profile with no dose-limiting toxicities. Based on these results, Jasper plans to commence a CSU registrational program with a Phase 2b study in the second half of 2025.
Jasper Therapeutics (Nasdaq: JSPR), a clinical-stage biotechnology company, will host a webinar on January 8, 2025, at 8am EST to present preliminary data from the BEACON study of briquilimab in Chronic Spontaneous Urticaria (CSU). This virtual event will feature remarks from Thomas B. Casale, M.D., Professor of Medicine and Pediatrics at the University of South Florida Morsani College of Medicine, who is the lead US investigator in the BEACON study. Briquilimab is a novel antibody therapy targeting c-Kit (CD117) and aims to address mast cell-driven diseases such as CSU, chronic inducible urticaria (CIndU), and asthma.
For those interested in attending, the registration details are as follows:
- Date: Wednesday, January 8, 2025
- Time: 8:00am EST
- Registration: Click Here
Jasper Therapeutics (Nasdaq: JSPR) has announced the first patient dosing in its Phase 1b/2a ETESIAN clinical study evaluating briquilimab in allergic asthma. The study will test a single 180mg subcutaneous dose of briquilimab in approximately 30 patients across up to 7 sites in Canada. This marks Jasper's third clinical program for briquilimab in inflammatory diseases driven by mast cell activity. The double-blind, placebo-controlled challenge study aims to demonstrate proof-of-concept in asthma, with initial data expected in the second half of 2025. Key assessments will include early and late asthmatic response, airway hyperresponsiveness, and mast cell depletion and recovery.
Jasper Therapeutics (Nasdaq: JSPR), a clinical stage biotech company developing briquilimab, announces its participation in three upcoming investor conferences. The company will present at the Stifel 2024 Healthcare Conference (Nov 18-19) with a fireside chat on Nov 18 at 9:45 AM ET, the Jefferies London Healthcare Conference (Nov 19-21), and the 7th Annual Evercore ISI HealthCONx Conference (Dec 3-5) with a fireside chat on Dec 3 at 3:25 PM ET. Briquilimab is a novel antibody therapy targeting c-Kit (CD117) for mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.
Jasper Therapeutics (JSPR) reported Q3 2024 financial results and provided updates on its briquilimab development programs. The company reported positive preliminary data from the SPOTLIGHT study in CIndU, with 93% of participants in the 40mg and 120mg dose cohorts achieving clinical response. Financial highlights include cash position of $92.5 million, R&D expenses of $14.5 million, and a net loss of $18.6 million ($1.24 per share). The company discontinued its LR-MDS program but advanced its chronic urticaria and asthma studies, with initial BEACON study data expected in January 2025.
Jasper Therapeutics (Nasdaq: JSPR) will present preclinical data for briquilimab, their novel antibody therapy targeting c-Kit (CD117), at the ACAAI Annual Scientific Meeting in Boston from October 24-28, 2024. The therapy aims to treat mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.
Three presentations will showcase promising preclinical results demonstrating briquilimab's effectiveness in mast cell depletion and its ability to bind c-Kit with high potency. The studies include both in-vitro data and non-human primate research, supporting the drug's pharmacodynamics. All presentations will take place on Friday, October 25, 2024, in Exhibit Hall A.
FAQ
What is the current stock price of Jasper Therapeutics (JSPR)?
What is the market cap of Jasper Therapeutics (JSPR)?
